A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

October 15, 2025

Study Completion Date

November 7, 2025

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Relatlimab

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Bevacizumab

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Trial Locations (61)

0

Local Institution - 0004, Hong Kong

404

Local Institution - 0043, District Taichung City

935

Local Institution - 0052, Rio Piedras

2050

Local Institution - 0045, Camperdown

3065

Local Institution - 0013, Melbourne

3084

Local Institution - 0026, Heidelberg

5000

Local Institution - 0022, Adelaide

6009

Local Institution - 0017, Nedlands

10048

Local Institution - 0046, Taipei

10065

Local Institution - 0061, New York

10461

Local Institution - 0062, The Bronx

11217

Local Institution - 0049, Taipei

13496

Local Institution - 0037, Seongnam-si

15706

Local Institution - 0032, Santiago de Compostela

20007

Local Institution - 0030, Washington D.C.

20122

Local Institution - 0036, Milan

21231

Local Institution - 0059, Baltimore

28027

Local Institution - 0067, Madrid

28046

Local Institution - 0053, Madrid

31008

Local Institution - 0038, Pamplona

35042

Local Institution - 0008, Rennes

35128

Local Institution - 0003, Padua

38043

Local Institution - 0012, Grenoble

39008

Local Institution - 0007, Santander

40225

Local Institution - 0051, Düsseldorf

40705

Local Institution - 0024, Taichung

50009

Local Institution - 0040, Zaragoza

51092

Local Institution - 0002, Reims

53226

Local Institution - 0033, Milwaukee

55131

Local Institution - 0057, Mainz

60590

Local Institution - 0035, Frankfurt

81377

Local Institution - 0055, Munich

84918

Local Institution - 0021, Avignon

90033

Local Institution - 0042, Los Angeles

90095

Local Institution - 0039, Los Angeles

92151

Local Institution - 0054, Suresnes

94115

Local Institution - 0034, San Francisco

168583

Local Institution - 0029, Singapore

217562

Local Institution - 0027, Singapore

308433

Local Institution - 0018, Singapore

329563

Local Institution - 0044, Singapore

510515

Local Institution - 0064, Guangzhou

710700

Local Institution - 0066, Xi'an

999077

Local Institution - 0031, Shatin

2320024

Local Institution - 0050, Yokohama

2778577

Local Institution - 0047, Kashiwa-shi

5898511

Local Institution - 0041, Sayama

7900024

Local Institution - 0048, Matsuyama

9208641

Local Institution - 0058, Kanazawa

02114

Local Institution - 0060, Boston

02215

Local Institution - 0065, Boston

T6G 1Z2

Local Institution - 0025, Edmonton

M5G 2M9

Local Institution - 0009, Toronto

06202

Local Institution - 0001, Nice

00168

Local Institution - 0010, Roma

104-0045

Local Institution - 0063, Chuo-ku

85-796

Local Institution - 0028, Bydgoszcz

02-034

Local Institution - 0016, Warsaw

80-219

Local Institution - 0023, Gdansk

00927

Local Institution - 0019, San Juan

138-736

Local Institution - 0056, Seoul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05337137 - A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | Biotech Hunter | Biotech Hunter